RecruitingACTRN12615000202561

Development of a Pathogen Blood Test for patients with Lyme-like symptoms

Patients with Lyme-like symptoms are tested for presence of infectious agents including Borrelia, Rickettsia, Babesia, and fungal infections by combining microscopy and genetic DNA analysis


Sponsor

National Institute of Integrative Medicine

Enrollment

1,000 participants

Start Date

Mar 31, 2015

Study Type

Interventional

Conditions

Summary

For chronic illnesses such as Lyme-like Illness, Chronic Fatigue Syndrome, and Chronic Pain, differential diagnosis is regularly made on the basis of signs and symptoms rather than specific medical tests. This means that the cause of such illnesses often remains unidentified. For Lyme Disease or Borreliosis, standard diagnostic testing typically involves indirect serology testing of antibodies made by the body in response to an infection or foreign agent. However, such indirect forms of testing can be problematic as antibodies produced in response to infection by a specific foreign agent can bind not only with antigens of the specific foreign agent, but also to antigens of other infectious agents. For instance, cross-reacting antibodies can be produced in response to both Borrelia burgdorferi bacteria (causative agent for Lyme disease) and certain types of viruses or other infections, potentially causing diagnostic confusion in interpreting the results of serological testing (such as Western blot technique). “Many diseases have been reported to cause significant cross-reactivity in IgM and/or IgG assays. Among such diseases are autoimmune disorders, Epstein-Barr virus infection, bacterial endocarditis, syphilis, other spirochetal infections, and Helicobacter pylori infection.” [Ref: Reed, Kurt D. "Laboratory testing for Lyme disease: possibilities and practicalities." Journal of clinical microbiology 40.2 (2002): 319-324.] Moreover, antibodies may circulate in the body long after an acute infection (for example, around ten to twenty years after a Borrelia infection), further adding to the diagnostic confusion. This observational study aims to identifying DNA containing non-human cells or pathogens present in a patient’s blood sample. The study combines blood filtration, microscopy and PCR-DNA genetic analysis.


Eligibility

Sex: Both males and femalesMin Age: 3 YearssMax Age: 90 Yearss

Plain Language Summary

Simplified for easier understanding

This study is developing a new blood test to detect non-human cells or genetic material (DNA) in the blood of people who have symptoms similar to Lyme disease — such as joint pain, extreme tiredness, or neurological problems. Standard blood tests for Lyme disease can sometimes give misleading results. This new approach uses a combination of filtering, microscopy, and genetic analysis to identify possible pathogens more directly. You may be eligible if: - You are between 3 and 90 years old - You are experiencing Lyme-like symptoms such as joint pain, chronic fatigue, or neurological problems - A treating doctor has suggested you may have a tick-borne infection - You may or may not know if you were bitten by a tick - You may or may not have had a previous diagnosis of Borrelia infection You may NOT be eligible if: - You are unable to give consent Talk to your doctor about whether this trial might be right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Patients presenting to the NIIM clinic with Lyme-like symptoms, including those with joint pain, chronic fatigue, and neurological conditions will be invited to undertake the Pathogen Blood test. The

Patients presenting to the NIIM clinic with Lyme-like symptoms, including those with joint pain, chronic fatigue, and neurological conditions will be invited to undertake the Pathogen Blood test. The first part of the test involves a Pathogen screen by filtration of 10 ml of blood and microscopy.The second part of the test involves DNA extraction out of whole blood and PCR-DNA analysis of infectious agents, specifically Borrelia bacteria, Rickettsia, Babesia and fungal pathogens. To further identify the nature of the fungal infection, the PCR products are sequenced.


Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12615000202561


Related Trials